Join us for a virtual KOL event with BioInvent, featuring Alexander Eggermont, MD, PhD (University Medical Center Utrecht), who will join company management to discuss the recently disclosed positive clinical data for BioInvent’s lead, first-in-class antibodies, BI-1808 and BI-1206, to be presented at ASCO and EHA. The data support the promise of FcyRIIB and TNFR2 as important immunotherapy targets. BI-1808 and BI-1206 are BioInvent’s two lead programs in a broad pipeline of first- or best-in-class immunomodulatory antibodies for the treatment of cancer:

• BI-1808, an anti-TNFR2 antibody, showing promising single-agent efficacy in an ongoing Phase 1/2a trial as a single agent as well as in combination with pembrolizumab for patients with advanced malignancies.
• BI-1206, an anti-FcyRIIB antibody, currently being evaluated in two Phase 1/2a trials: in combination with rituximab for patients with non-Hodgkin’s lymphoma (NHL) and in combination with pembrolizumab for patients with solid tumors. Recently disclosed data for BI-1206 show long-lasting responses in heavily pre-treated patients.

The event will include an overview of the company’s development strategy and highlight upcoming rich news flow for the rest of 2024.

A live question and answer session will follow the formal presentation.